Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,361 across all filing types
Latest filing 2024-12-02 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 亚宝药业集团股份有限公司. It details the number of shares repurchased, prices, total amount spent, and compliance with relevant regulations. It does not contain full financial statements or comprehensive financial analysis but rather updates on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back its own shares.
2024-12-02 Chinese
亚宝药业集团股份有限公司关于全资子公司取得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 亚宝药业集团股份有限公司 regarding its wholly-owned subsidiary obtaining a drug registration certificate from the National Medical Products Administration. It details the drug name, specifications, approval number, and related information. The document is short (1192 characters) and serves as a formal notification of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a regulatory announcement category related to compliance and approvals. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-11-21 Chinese
亚宝药业集团股份有限公司关于召开2024年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 third quarter earnings explanation meeting (业绩说明会) for investors. It provides the date, time, location, participation method, and contact information for the meeting. It references the previously published 2024 third quarter report but does not contain the actual financial data or detailed financial analysis itself. The document is short (1437 characters) and serves as a notice for an upcoming earnings call or presentation rather than the earnings release or the full quarterly report. Therefore, it is best classified as an Investor Presentation (IP) announcement or related to an earnings call event. Given the content focuses on the earnings explanation meeting, the most appropriate classification is Investor Presentation (IP).
2024-11-04 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 亚宝药业集团股份有限公司. It details the number of shares repurchased, prices, total amount spent, and compliance with relevant regulations. The document does not contain full financial statements or comprehensive financial analysis but focuses on the update of the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-11-01 Chinese
亚宝药业集团股份有限公司2024年第三季度报告（修订版）
Interim / Quarterly Report Classification · 100% confidence The document is titled "亚宝药业集团股份有限公司 2024 年第三季度报告" which translates to "Yabao Pharmaceutical Group Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and notes for the third quarter of 2024. The report explicitly states it is a quarterly report and includes unaudited financial statements for the quarter ending September 30, 2024. The length of the document (15,000 characters) and the presence of comprehensive financial data confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-25 Chinese
亚宝药业集团股份有限公司2024年第三季度报告更正公告
Regulatory Filings Classification · 95% confidence The document is titled as a "2024 Third Quarter Report Correction Announcement" and it refers to a previously published third quarter report with a correction to shareholder information. The document is short (1080 characters) and primarily announces a correction to a previously released quarterly report rather than presenting the full financial data itself. It also directs readers to the Shanghai Stock Exchange website for the corrected report. This fits the pattern of a Regulatory Filing (RNS) as it is an announcement of a correction rather than the full interim report itself. Therefore, it should not be classified as an Interim/Quarterly Report (IR) but as a Regulatory Filing (RNS).
2024-10-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.